Y-mAbs soars on take-private deal with SERB Pharmaceutical

2 hours ago 1

• Healthcare
• On the Move
• M&A

mbbirdy/E+ via Getty Images

Y-mAbs Therapeutics (NASDAQ:YMAB) is set to go private after SERB Pharmaceuticals announced on Tuesday that it would buy the cancer drug developer for an estimated $412M in equity value.

The stock more than doubled as trading resumed post premarket halt.

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Y-mAbs soars on take-private deal with SERB Pharmaceutical